Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:37:32.888Z.
Consensus retrieved: 2026-10-06T12:44:17.471Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:37:32.888Z.
Quote observation: 2026-10-06T13:34:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09addc1f717f3fcbea893576410d9510599f2212689b268ebecba03dec8a4f18
FORWARD PE RATIO
N/A
Immatics N.V.
Market Cap
$1.03B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Immatics N.V. (IMTX) | $1.03B | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.02B | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.05B | 5.51 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.06B | 17.14 |
| Aktis Oncology, Inc. (AKTS)vs › | $988.93M | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.21M | N/A |
| IRadimed Corporation (IRMD)vs › | $1.11B | 41.14 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in EUR, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
